Stock Events

Shield Therapeutics 

€0.03
2
+€0+0% Thursday 07:00

Statistics

Day High
0.03
Day Low
0.03
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
20.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30JunConfirmed
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
-0.03
-0.01
0
0.02
Expected EPS
0
Actual EPS
-0.0275

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1JS.F. It's not an investment recommendation.

About

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Show more...
CEO
Mr. Gregory P. Madison
Employees
15
Country
GB
ISIN
GB00BYV81293
WKN
000A2AE98

Listings